跳到正文
營養與代謝隨機對照試驗3 分鐘閱讀

在胰島素基礎上加三株益生菌,與1型糖尿病患者血糖改善相關

MoveVitals 編輯部 · 研究發表 · 解讀更新

原文:Adjuvant Probiotics of Lactobacillus salivarius subsp. salicinius AP-32, L. johnsonii MH-68, and Bifidobacterium animalis subsp. lactis CP-9 Attenuate Glycemic Levels and Inflammatory Cytokines in Patients With Type 1 Diabetes Mellitus. · Frontiers in endocrinology · 2022 · 論文原文 ↗

先看重點

在6至18歲1型糖尿病患者的雙盲試驗中,胰島素基礎上加用三株益生菌6個月後,空腹血糖和糖化血紅蛋白(HbA1c)較治療前降低,多種炎症指標下降。益生菌組僅27人,摘要也未給出具體效應數值,這只是早期訊號,不能證明確有獲益。

證據類型

隨機對照試驗

解讀依據

公開摘要

閱讀重點

對照與不確定性

研究在問什麼

1型糖尿病(T1DM)是免疫系統破壞胰腺產生胰島素的β細胞所致,而腸道細菌參與免疫調節。作者檢驗了在常規胰島素基礎上加用特定益生菌,能否改善血糖控制(HbA1c)和炎症指標,以及益生菌如何改變腸道菌群。

研究對象與方法

在中國醫藥大學附設醫院開展的隨機、雙盲、安慰劑對照試驗(ClinicalTrials.gov編號NCT03880760),納入6至18歲的T1DM患者。27名患者在常規胰島素基礎上每日服用含唾液乳桿菌AP-32、約氏乳桿菌MH-68和乳雙歧桿菌CP-9的膠囊,共6個月;29名患者只用胰島素、不加益生菌,作為安慰劑組。觀察空腹血糖和HbA1c,用酶聯免疫吸附法檢測促炎與抗炎細胞因子,並用二代測序(NGS)分析糞便菌群。

主要發現

以下為作者報告的結果。數值須連同族群和不確定性一起閱讀。

  1. 1
    腸道測序顯示,服用益生菌的患者腸道中動物雙歧桿菌、嗜黏蛋白阿克曼菌和唾液乳桿菌的數量增加。
  2. 2
    益生菌治療後空腹血糖較介入前顯著降低,HbA1c也有所改善。摘要沒有給出具體數值,也未給出與安慰劑組的直接比較。
  3. 3
    益生菌介入後,IL-8、IL-17、MIP-1β、RANTES和TNF-α濃度顯著降低,同時TGF-β1表達增加。
  4. 4
    停用益生菌3個月後,血糖控制和免疫調節的改善仍然存在。

限制與不確定性

  1. 1
    這是一項小型試驗(益生菌組27人,安慰劑組29人),來自一家醫院,且只涉及兒童和青少年。
  2. 2
    血糖結果表述為治療前後的變化,摘要未給出數值,因此無法判斷變化中有多少超出了安慰劑組。
  3. 3
    所用益生菌是三個特定菌株的組合,結果不能推廣到其他益生菌產品。
  4. 4
    血糖和細胞因子的變化不能說明併發症或低血糖等長期結局。本解讀僅基於摘要。

日常健康啟示

這項早期試驗提示,在胰島素之外加用特定的益生菌組合,可能改善1型糖尿病青少年的血糖和炎症指標。這並不意味著益生菌能代替或減少胰島素,三個特定菌株的結果也不能套用到貨架上的產品。調整糖尿病治療前,應與糖尿病團隊商量。

如何連結自己的資料

對1型糖尿病患者來說,持續葡萄糖監測(CGM)的達標時間和HbA1c是應該與醫療團隊一起關注的數字。建議用同一感測器比較相似的幾週,不要因為服用補充劑而自行停用或更改胰島素。

如何理解這類證據

隨機分組有助於因果推斷,仍須檢查分配、盲法、失去追蹤、追蹤時間和具體對照;標為隨機試驗不自動意味著高確定性。

作者的結構化摘要 English

以下英文摘要依所記錄的開放授權轉載,屬於作者原始材料,並非 MoveVitals 解讀。上方已提供研究解讀,分別說明作者結果與本站解釋;重要結論可直接查核原文。

Introduction

Type 1 diabetes mellitus (T1DM) is characterized by autoimmune destruction of pancreatic β cells. Previous study has discovered that probiotic strains residing in the gut play essential roles in host immune regulation. However, few clinical results demonstrated probiotic would actually benefit in attenuating glycated hemoglobin (HbA1c) along with inflammatory cytokine levels of the T1DM patients and analyzed their gut microbiota profile at the same time. In this clinical trial, we evaluated the therapeutic efficacy of probiotics on HbA1c along with inflammatory cytokine levels of T1DM patients to determine an alternative administration mode for T1DM medication. The probiotics changed T1DM gut microbiota profile will be measured by next-generation sequencing (NGS).

Research design and methods

A randomized, double-blind, placebo-controlled trial was performed at China Medical University Hospital. T1DM patients between 6 and 18 years of age were enrolled. 27 patients were administered regular insulin therapy plus capsules containing probiotic strains Lactobacillus salivarius subsp. salicinius AP-32, L. johnsonii MH-68, and Bifidobacterium animalis subsp. lactis CP-9 daily for 6 months, and 29 patients were administered insulin therapy without extra probiotic supplement as placebo group. The variations of fasting blood glucose and HbA1c in these patients were analyzed. In addition, serum levels of inflammatory cytokines and anti-inflammatory cytokine were assessed using enzyme-linked immunosorbent assay. Patients' stool microbiota were all subjects to NGS analysis.

Results

NGS data showed elevated populations of Bifidobacterium animalis, Akkermansia muciniphila and Lactobacillus salivarius in the gut of patients with T1DM who were taking probiotics. Patients with T1DM who were administered probiotics showed significantly reduced fasting blood glucose levels compared with the before-intervention levels. The HbA1c levels of the patients also improved after administration of probiotics. The concentrations of IL-8, IL-17, MIP-1β, RANTES, and TNF-α were significantly reduced and were associated with an increased TGF-β1 expression after probiotic intervention. The persistence effect of glycemic control and immunomodulation were observed even 3 months after discontinuation of the probiotics.

Conclusions

Here, we found that conventional insulin therapy plus probiotics supplementation attenuated T1DM symptoms than receiving insulin treatment only. Probiotics supplementation with insulin treatment changed gut microbiota and revealed better outcome in stabilizing glycemic levels and reducing HbA1c levels in patients with T1DM through beneficial regulation of immune cytokines.

Clinical trial registration

ClinicalTrials.gov, identifier NCT03880760.

來源與署名

Adjuvant Probiotics of Lactobacillus salivarius subsp. salicinius AP-32, L. johnsonii MH-68, and Bifidobacterium animalis subsp. lactis CP-9 Attenuate Glycemic Levels and Inflammatory Cytokines in Patients With Type 1 Diabetes Mellitus.

Wang CH, Yen HR, Lu WL, Ho HH, Lin WY, Kuo YW, Huang YY, Tsai SY, Lin HC.

Frontiers in endocrinology · 2022-03-01

DOI: 10.3389/fendo.2022.754401 ↗PubMed · 35299968 ↗Europe PMC · 所記錄的開放授權: cc by ↗

摘要著作權歸原作者,依來源紀錄的開放授權轉載。中文譯文協助閱讀,英文摘要供查核術語及具體數值;本站的方法學解釋與作者結論分別呈現。

MoveVitals 編輯解讀 · 健康教育內容 · 未記錄個人臨床審閱

來源查核日期 2026-11-01

實用健康指南

放在一起讀

·隨機試驗統合分析

更早的進食視窗與更大的體重和胰島素獲益相關,優於晚間進食

彙總41項隨機對照試驗(2287名參與者,介入時間中位數8週)發現,限時進食比日常飲食體重低2.15 kg(95%置信區間−2.56至−1.74),而早吃比晚吃體重多降1.15 kg(95%置信區間−1.86至−0.45)。多數試驗較短,只有6個研究組檢驗了早間進食,結局是身體和血液指標,不是心臟病發作或死亡。

BMJ Medicine

重點論文精講閱讀論文 →
·隨機對照試驗

限熱量飲食再加上午8點至下午4點進食視窗,1年減重無明顯額外優勢

139名肥胖患者都按限制熱量的飲食進食,其中一組再加上上午8:00至下午4:00的進食視窗,12個月平均體重變化為−8.0 kg,單純限熱量組為−6.3 kg。淨差值−1.8 kg(95%置信區間−4.0至0.4;P=0.11)無統計學意義,該區間既不能排除視窗確有獲益,也不能排除毫無作用。

The New England Journal of Medicine

重點論文精講閱讀論文 →
·隨機對照試驗

20人住院試驗:超加工飲食讓人每天多攝取508 kcal並增重

20名成年人在醫院研究病房住了28天,兩種選單各吃2週、想吃多少吃多少:超加工選單讓他們每天多攝取508 kcal(±106,標準誤,P=0.0001),體重增加0.9 kg;未加工選單則讓體重減輕0.9 kg。樣本小、週期短、食物全程由研究方提供,既不能說明日常生活中的長期結果,也無法確定是食物的哪種特點導致多吃。

Cell Metabolism

重點論文精講閱讀論文 →
·隨機對照試驗

地中海飲食加橄欖油或堅果與心血管事件減少相關(更正後的試驗)

在7447名55至80歲、心血管風險較高的西班牙成年人中,被分到加特級初榨橄欖油(風險比0.69,95%置信區間0.53至0.91)或加堅果(風險比0.72,0.54至0.95)的地中海飲食組,發生主要心血管事件的風險低於被告知減少脂肪的對照組。試驗存在隨機化失誤,2013年的報告已撤回並重新估算,證據有力但並不完美。

The New England Journal of Medicine

重點論文精講閱讀論文 →
營養與代謝 →